Stroke and recurrent haemorrhage associated with antithrombotic treatment after gastrointestinal bleeding in patients with atrial fibrillation: Nationwide cohort STUDY

BMJ (Online)

Volumn 351, Issue , 2015, Pages

  Staerk, Laila ^a,b   Lip, Gregory Y H ^b   Olesen, Jonas B ^a   Fosbøl, Emil L ^c   Pallisgaard, Jannik L ^a   Bonde, Anders N ^a   Gundlund, Anna ^a   Lindhardt, Tommi B ^a   Hansen, Morten L ^c   Torp Pedersen, Christian ^d   Gislason, Gunnar H ^a,e,f,g  

^a GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d AALBORG UNIVERSITY   (Denmark)

^e UNIVERSITY OF COPENHAGEN   (Denmark)

^f UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^g The Danish Heart Foundation   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE RECEPTOR BLOCKING AGENT; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; DABIGATRAN; PROTON PUMP INHIBITOR; RIVAROXABAN; FIBRINOLYTIC AGENT;

AGED; ANTICOAGULANT THERAPY; ARTICLE; ATRIAL FIBRILLATION; CAUSE OF DEATH; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; FOLLOW UP; GASTROINTESTINAL HEMORRHAGE; HUMAN; INCIDENCE; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RECURRENT DISEASE; RISK ASSESSMENT; RISK FACTOR; RISK REDUCTION; SENSITIVITY ANALYSIS; THROMBOEMBOLISM; CHEMICALLY INDUCED; CLINICAL TRIAL; COMPLICATION; DENMARK; MULTICENTER STUDY; PROPORTIONAL HAZARDS MODEL; REGISTER; STROKE; SURVIVAL RATE; TRENDS;

AGED; ATRIAL FIBRILLATION; DENMARK; FEMALE; FIBRINOLYTIC AGENTS; GASTROINTESTINAL HEMORRHAGE; HUMANS; INCIDENCE; MALE; PROPORTIONAL HAZARDS MODELS; RECURRENCE; REGISTRIES; RISK FACTORS; STROKE; SURVIVAL RATE;

EID: 84951774817     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.h5876     Document Type: Article

References (34)

1. Lip GH, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. JAMA 2015;313:1950-62.
2. Camm AJ, Lip GYH, Caterina RD, et al. 2012 focused update of the ESC guidelines for the management of atrial fibrillation: an update of the 2010 ESC guidelines for the management of atrial fibrillation-developed with the special contribution of the European Heart Rhythm Association. Europace 2012;14:1385-413.
3. Sam C, Massaro JM, D'Agostino RB Sr, et al. Warfarin and aspirin use and the predictors of major bleeding complications in atrial fibrillation (the Framingham Heart Study). Am J Cardiol 2004;94:947-51.
4. Hansen ML, Sørensen R, Clausen MT, et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010;170:1433-41.
5. Choudari CP, Palmer KR. Acute gastrointestinal haemorrhage in patients treated with anticoagulant drugs. Gut 1995;36:483-4.
6. Man-Son-Hing M, Laupacis A. Balancing the risks of stroke and upper gastrointestinal tract bleeding in older patients with atrial fibrillation. Arch Intern Med 2002;162:541-50.
7. Camm AJ, Kirchhof P, Lip GYH, et al. Guidelines for the management of atrial fibrillation. The Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Europace 2010;12:1360-420.
8. Alberts MJ, Eikelboom JW, Hankey GJ. Antithrombotic therapy for stroke prevention in non-valvular atrial fibrillation. Lancet Neurol 2012;11:1066-81.
9. Qureshi W, Mittal C, Patsias I, et al. Restarting anticoagulation and outcomes after major gastrointestinal bleeding in atrial fibrillation. Am J Cardiol 2014;113:662-8.
10. Riva N, Apostolakis S, Lip GYH. Oral antithrombotic therapy and gastrointestinal bleeding: the good, the bad and the ugly. Int J Clin Pract 2012;66:2-4.
11. Lynge E, Sandegaard JL, Rebolj M. The Danish National Patient Register. Scand J Public Health 2011;39:30-3.
12. Kildemoes HW, Sørensen HT, Hallas J. The Danish National Prescription Registry. Scand J Public Health 2011;39:38-41.
13. Pedersen CB. The Danish Civil Registration System. Scand J Public Health 2011;39:22-5.
14. Cunningham A, Stein CM, Chung CP, et al. An automated database case definition for serious bleeding related to oral anticoagulant use. Pharmacoepidemiol Drug Saf 2011;20:560-6.
15. Lamberts M, Olesen JB, Ruwald MH, et al. Bleeding after initiation of multiple antithrombotic drugs, including triple therapy, in atrial fibrillation patients following myocardial infarction and coronary intervention: a nationwide cohort study. Circulation 2012;126:1185-93.
16. Olesen JB, Lip GYH, Lindhardsen J, et al. Risks of thromboembolism and bleeding with thromboprophylaxis in patients with atrial fibrillation: a net clinical benefit analysis using 'real world' nationwide cohort study. Thromb Haemost 2011;106:739-49.
17. Olesen JB, Lip GYH, Hansen ML, et al. Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort study. BMJ 2011;342:d124.
18. Kümler T, Gislason GH, Kirk V, et al. Accuracy of a heart failure diagnosis in administrative registers. Eur J Heart Fail 2008;10:658-60.
19. Krarup L-H, Boysen G, Janjua H, et al. Validity of stroke diagnoses in a national register of patients. Neuroepidemiology 2007;28:150-4.
20. Madsen M, Davidsen M, Rasmussen S, et al. The validity of the diagnosis of acute myocardial infarction in routine statistics: a comparison of mortality and hospital discharge data with the Danish MONICA registry. J Clin Epidemiol 2003;56:124-30.
21. Olesen JB, Sørensen R, Hansen ML, et al. Non-vitamin K antagonist oral anticoagulation agents in anticoagulant naïve atrial fibrillation patients: Danish nationwide descriptive data 2011-2013. Europace 2015;17:187-93.
22. Gooley TA, Leisenring W, Crowley J, et al. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med 1999;18:695-706.
23. Hearnshaw SA, Logan RFA, Lowe D, et al. Acute upper gastrointestinal bleeding in the UK: patient characteristics, diagnoses and outcomes in the 2007 UK audit. Gut 2011;60:1327-35.
24. Lau JY, Barkun A, Fan D, et al. Challenges in the management of acute peptic ulcer bleeding. Lancet 2013;381:2033-43.
25. Lip GYH. Don't add aspirin for associated stable vascular disease in a patient with atrial fibrillation receiving anticoagulation. BMJ 2008;336:614-5.
26. Connolly SJ, Ezekowitz MD, Yusuf S, et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009;361:1139-51.
27. Witt DM, Delate T, Garcia DA, et al. Risk of thromboembolism, recurrent hemorrhage, and death after warfarin therapy interruption for gastrointestinal tract bleeding. Arch Intern Med 2012;172:1484-91.
28. Sung JJY, Lau JYW, Ching JYL, et al. Continuation of low-dose aspirin therapy in peptic ulcer bleeding: a randomized trial. Ann Intern Med 2010;152:1-9.
29. Bhatt DL, Scheiman J, Abraham NS, et al. ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use: a report of the American College of Cardiology Foundation Task Force on clinical expert consensus documents. J Am Coll Cardiol 2008;52:1502-17.
30. Abraham NS, Hlatky MA, Antman EM, et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. J Am Coll Cardiol 2010;56:2051-66.
31. Delaney JA, Opatrny L, Brophy JM, et al. Drug-drug interactions between antithrombotic medications and the risk of gastrointestinal bleeding. Can Med Assoc J 2007;177:347-51.
32. Gaist D, Andersen M, Aarup A-L, et al. Use of sumatriptan in Denmark in 1994-5: an epidemiological analysis of nationwide prescription data. Br J Clin Pharmacol 1997;43:429-33.
33. Mukamal KJ, Tolstrup JS, Friberg J, et al. Alcohol consumption and risk of atrial fibrillation in men and women: the Copenhagen City Heart Study. Circulation 2005;112:1736-42.
34. Schmidt M, Hallas J, Friis S. Potential of prescription registries to capture individual-level use of aspirin and other nonsteroidal anti-inflammatory drugs in Denmark: trends in utilization 1999-2012. Clin Epidemiol 2014;6:155-68.